TG THERAPEUTICS, INC.

(TGTX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/12/2022 05/13/2022 05/16/2022 05/17/2022 05/18/2022 Date
6.04(c) 6.5(c) 6.47(c) 6.82(c) 6.1(c) Last
2 957 425 3 047 446 1 895 399 2 690 378 2 396 295 Volume
+5.78% +7.62% -0.46% +5.41% -10.56% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 22,9 M - -
Net income 2022 -247 M - -
Net cash position 2022 11,7 M - -
P/E ratio 2022 -3,47x
Yield 2022 -
Sales 2023 114 M - -
Net income 2023 -221 M - -
Net cash position 2023 41,9 M - -
P/E ratio 2023 -4,15x
Yield 2023 -
Capitalization 811 M 811 M -
EV / Sales 2022 34,9x
EV / Sales 2023 6,78x
Nbr of Employees 286
Free-Float 91,9%
More Financials
Company
TG Therapeutics, Inc. (TG) is a fully integrated, commercial stage biopharmaceutical company, which is focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. Its pipeline candidates include TG-1501 (Cosibelimab), TG-1701 (BTK inhibitor), TG-1801 (anti-CD47/anti-CD19 bispecific monoclonal antibody). Its UKONIQ (umbralisib) is developed for the... 
More about the company
Ratings of TG Therapeutics, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about TG THERAPEUTICS, INC.
05/11SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investors of TG Th..
PR
05/11TG THERAPEUTICS : Q1 Earnings Snapshot
AQ
05/10TG THERAPEUTICS, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND ..
AQ
05/10TG Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 20..
CI
04/27TG Therapeutics to Participate in the B. Riley Securities' 2022 Virtual Neuro & Ophthal..
AQ
04/26TG Therapeutics to Participate in the B. Riley Securities' 2022 Virtual Neuro & Ophthal..
AQ
04/25SHAREHOLDER ALERT : Pomerantz Law Firm Investigates Claims On Behalf of Investors of TG Th..
PR
04/19B. Riley Lowers TG Therapeutics' PT to $23 from $35, Says Exit from Oncology 'Disappoin..
MT
04/18TG Therapeutics Down More Than 20% After Dropping Biologics License Application for Leu..
MT
04/18Top Midday Decliners
MT
04/18TG Therapeutics Announces Voluntary Withdrawal of the BLA/sNDA for U2 to Treat Patients..
AQ
04/18SECTOR UPDATE : Health Care Stocks Modestly Lower Pre-Bell Monday
MT
04/18Wall Street Set for Narrow Losses Amid Rising Bond Yields
MT
04/18SECTOR UPDATE : Health Care
MT
04/18TRANSCRIPT : TG Therapeutics, Inc. - Special Call
CI
More news
News in other languages on TG THERAPEUTICS, INC.
05/10TG Therapeutics, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2..
04/18TG Therapeutics en baisse de plus de 20 % après l'abandon de la demande de licence biol..
04/18MISE À JOUR SECTORIELLE : Soins de santé
04/18TG Therapeutics abandonne une demande de licence de produits biologiques pour un traite..
04/15TG Therapeutics, Inc. annonce le retrait volontaire de la BLA/sNDA pour U2 pour traiter..
More news
Analyst Recommendations on TG THERAPEUTICS, INC.
More recommendations
Chart TG THERAPEUTICS, INC.
Duration : Period :
TG Therapeutics, Inc. Technical Analysis Chart | TGTX | US88322Q1085 | MarketScreener
Technical analysis trends TG THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 6,10 $
Average target price 19,63 $
Spread / Average Target 222%
EPS Revisions
Managers and Directors
Michael Sean Weiss Chairman, President & Chief Executive Officer
Sean A. Power Chief Financial Officer, Secretary & Treasurer
Owen A. O'Connor Chief Scientific Officer
Laurence N. Charney Lead Independent Director
Yann Echelard Independent Director
Sector and Competitors
1st jan.Capi. (M$)
TG THERAPEUTICS, INC.-67.89%811
MODERNA, INC.-45.78%54 775
LONZA GROUP AG-29.81%40 137
IQVIA HOLDINGS INC.-30.08%37 337
SEAGEN INC.-7.50%26 323
ICON PUBLIC LIMITED COMPANY-34.37%16 524